Epigenomics.com - SEO Checker

Sign up for free! PDF Export
Overview of the SEO Check
Meta information
72% 
Page quality
40% 
Page structure
71% 
Link structure
72% 
Server
92% 
External factors
100% 
SEO Score
Response time
0.55 s
File size
35.10 kB
Words
674
Media files
7
Number of links
70 internal / 1 external

Task list of SEO Improvements

Meta specifications

Title
(Critically important)
Home - epigenomics
The page title is too short. (186 pixels of 580 max pixel length) Optimize title
There are no duplicate words in the title
Meta description
(Critically important)
The meta description is missing.
Crawlability
(Critically important)
There are no problems in accessing the website.
Canonical URL
(Important)
https://www.epigenomics.com/
There is a valid canonical link specified.
Language
(Somewhat important)
Language detected in text: en
Language defined in HTML: en
Server location: United States of America
The following language is defined by HTML: en
Alternate/Hreflang Links
(Somewhat important)
Language for link pointing to page itself inaccurate
Other meta tags
(Somewhat important)
There is no rel next meta tag on this page.
There is no rel prev meta tag on this page.
Domain
(Somewhat important)
The domain is no subdomain.
The domain length is good.
The domain does not contain non-latin characters.
Page URL
(Somewhat important)
No parameters were found in the URL.
No session ID was found in the URL.
The URL does not have too many subdirectories.
Charset encoding
(Somewhat important)
The charset encoding (UTF-8) is set correctly.
Doctype
(Nice to have)
The doctype HTML 5 is set correctly.
The doctype is placed at first in the HTML code.
Favicon
(Nice to have)
No favicon is linked in the HTML code.

Meta tags

NameValue
viewportwidth=device-width, initial-scale=1
google-site-verificationbFluPtQiDjMZ6YuXXjGWjQNI4v8gamyu6jLX_w94kk8
generatorWPML ver:4.1.3 stt:1,3;
langen
twitter:cardsummary
twitter:descriptionEpigenomcs AG acts as a holding company and is dedicated to managing its own assets, acquiring, holding and disposing of investments in companies in Germany and abroad, particularly in the field of minimally invasive blood tests for cancer detection, as well as investing in other assets.   Latest News
twitter:titleHome - epigenomics
og:localeen_US
og:typewebsite
og:titleHome - epigenomics
og:descriptionEpigenomcs AG acts as a holding company and is dedicated to managing its own assets, acquiring, holding and disposing of investments in companies in Germany and abroad, particularly in the field of minimally invasive blood tests for cancer detection, as well as investing in other assets.   Latest News
og:urlhttps://www.epigenomics.com/
og:site_nameepigenomics
X-UA-CompatibleIE=edge
charsetutf-8

Test up to 1.000 webpages of epigenomics.com with our free plan!

Try For Free
No trial. It's just free!

Page quality

Content
(Critically important)
There are 2 text duplicates on this page:
  • Duplicate: Gesamtstimmrechte | 10 April 2024 11:33 Epigenomics AG / Total Voting ...
The average number of words per sentence of 55.57 words is high.
This page contains 674 words. That's ok.
19.3% of the text are stop words.
The page contains a listing, which indicates a good text layout.
7 paragraphs were found on this page.
The text content is perfect.
No placeholders texts or images were found.
Frames
(Critically important)
This page does not use a frameset.
Mobile optimization
(Somewhat important)
No Apple touch icon is specified.
A viewport "width=device-width, initial-scale=1" is provided.
Bold and strong tags
(Somewhat important)
The usage of strong and bold tags is perfect. We recommend the use of up to 13 tags for this page.
Image SEO
(Somewhat important)
4 images have no alt attribute. The content of alt attributes is used by search engines.
Social Networks
(Nice to have)
There are only a few social sharing widgets on the page. Make your website popular in social networks with social sharing widgets.
Additional markup
(Nice to have)
No additional page markup was found.
HTTPS
(Somewhat important)
This website uses HTTPS to protect privacy and integrity of the exchanged data.
All included files are also transferred via HTTPS.

Media list

URLAlt attributeTitle
...ntent/themes/epigenomics/images/logo.pngDetecting cancer in blood
...ntent/themes/epigenomics/images/home.svgHome
...t/themes/epigenomics/images/social-f.pngNo alt attribute provided
.../themes/epigenomics/images/social-li.pngNo alt attribute provided
...t/themes/epigenomics/images/social-e.pngNo alt attribute provided
...emes/epigenomics/images/man-vs-woman.pngman-vs-woman

Page structure

H1 heading
(Critically important)
There is no H1 heading specified.
Headings
(Important)
Some headings occur twice on the page.
The structure of headings is missing one or more levels. Do not skip heading levels.
Some headings do not have any content.

Heading structure

Heading levelContent
H2 Empty heading
H2 Latest News
H2 Epigenomics AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
H2 Epigenomics AG: Preliminary half-year results as at June 30, 2024
H2 Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
H2 Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024
H2 Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution Duplicate text
H2 Epigenomics AG publishes financial results for fiscal year 2023
H6 Epigenomics AG
Some internal link anchor texts are too long.
Some anchor texts are used more than once.
The number of internal links is ok.
All internal links are not using dynamic parameters.
There are 1 external links on this page.

Found links on this page

LinkAttributesAnchor text
/company/Subdomain Company
/company/about-us/Subdomain About us
/company/management/Subdomain Management
/company/supervisory-board/Subdomain Supervisory Board
/news-investors/Subdomain News & Investors
/news-investors/share-informat...Subdomain Share information
/news-investors/share-informat...Subdomain Shareholders
/news-investors/share-informat...Subdomain Analyst coverage
/news-investors/share-informat...Subdomain Share Price
/news-investors/ad-hoc-releases/Subdomain News
/category/press-releases/Subdomain Press Releases
/category/voting-rights/Subdomain Voting Rights
/category/other-mandatory-anno...Subdomain Other mandatory announcements
/news-investors/financial-repo...Subdomain Financial Reports
/news-investors/corporate-gove...Subdomain Corporate Governance
/company/supervisory-board/Subdomain Text duplicate Supervisory Board
/category/directors-dealings/Subdomain Directors’ Dealings
/news-investors/corporate-gove...Subdomain Remuneration
/news-investors/general-shareh...Subdomain General Shareholders’ Meeting
/news-investors/financial-cale...Subdomain Financial Calendar
/news-investors/convertible-bo...Subdomain Mandatory convertible bond 2021/2024
/news-investors/convertible-bo...Subdomain Mandatory convertible bond 2021/2027
/news-investors/disclaimer-cap...Subdomain Capital increase 2021
/news-investors/capital-increase/Subdomain Capital increase 2019
/news-investors/contact/Subdomain Contact
/contact-form/Subdomain Text duplicate Contact
https://www.netgenerator.de/re...New window External Subdomain Pharma Webdesign Berlin
A-TITLE Die Webdesign-Agentur für die Pharma-Branche
https://www.epigenomics.com/Subdomain IMG-ALT Detecting cancer in blood
A-TITLE Detecting cancer in blood
https://www.epigenomics.com/Anchor Menu
A-TITLE Menu
https://www.epigenomics.com/Subdomain IMG-ALT Home
A-TITLE Detecting cancer in blood
https://www.epigenomics.com/Subdomain en
https://www.epigenomics.com/de/Subdomain de
/company/Subdomain Text duplicate Company
/company/about-us/Subdomain Text duplicate About us
/company/management/Subdomain Text duplicate Management
/company/supervisory-board/Subdomain Text duplicate Supervisory Board
/news-investors/Subdomain Text duplicate News & Investors
/news-investors/share-informat...Subdomain Text duplicate Share information
/news-investors/share-informat...Subdomain Text duplicate Shareholders
/news-investors/share-informat...Subdomain Text duplicate Analyst coverage
/news-investors/share-informat...Subdomain Text duplicate Share Price
/news-investors/ad-hoc-releases/Subdomain Text duplicate News
/category/press-releases/Subdomain Text duplicate Press Releases
/category/voting-rights/Subdomain Text duplicate Voting Rights
/category/other-mandatory-anno...Subdomain Text duplicate Other mandatory announcements
/news-investors/financial-repo...Subdomain Text duplicate Financial Reports
/news-investors/corporate-gove...Subdomain Text duplicate Corporate Governance
/company/supervisory-board/Subdomain Text duplicate Supervisory Board
/category/directors-dealings/Subdomain Text duplicate Directors’ Dealings
/news-investors/corporate-gove...Subdomain Text duplicate Remuneration
/news-investors/general-shareh...Subdomain Text duplicate General Shareholders’ Meeting
/news-investors/financial-cale...Subdomain Text duplicate Financial Calendar
/news-investors/convertible-bo...Subdomain Text duplicate Mandatory convertible bond 2021/2024
/news-investors/convertible-bo...Subdomain Text duplicate Mandatory convertible bond 2021/2027
/news-investors/disclaimer-cap...Subdomain Text duplicate Capital increase 2021
/news-investors/capital-increase/Subdomain Text duplicate Capital increase 2019
/news-investors/contact/Subdomain Text duplicate Contact
/contact-form/Subdomain Text duplicate Contact
/epigenomics-ag-preliminary-an...Subdomain Epigenomics AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
/epigenomics-ag-preliminary-ha...Subdomain Epigenomics AG: Preliminary half-year results as at June 30, 2024
/epigenomics-ag-release-accord...Subdomain Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
/epigenomics-ag-executive-boar...Subdomain Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024
/epigenomics-ag-executive-boar...Subdomain Anchor 0 comments
/epigenomics-ag-release-accord...Subdomain Text duplicate Epigenomics AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
/epigenomics-ag-publishes-fina...Subdomain Epigenomics AG publishes financial results for fiscal year 2023
/epigenomics-ag-publishes-fina...Subdomain Anchor Text duplicate 0 comments
https://www.epigenomics.com/Subdomain Text duplicate Home
/news-investors/contact/Subdomain Text duplicate Contact
/imprint/Subdomain Imprint
/imprint/data-protection-state...Subdomain Data Protection Statement
/imprint/disclaimer/Subdomain Disclaimer

Server configuration

HTTP redirects
(Critically important)
The checked page does not redirect to another URL.
HTTP header
(Important)
No X-Powered HTTP header is sent.
This page uses GZip for compressed data transmission.
Performance
(Somewhat important)
The page response time of 0.55 seconds is longer than the recommended limit of 0.4 seconds. A high response time unnecessarily slows down search engine crawling and results in bad user experience as well.
The file size of the HTML document is fine (35 kB).

HTTP Response Header

NameValue
link<https://www.epigenomics.com/wp-json/>; rel="https://api.w.org/", <https://www.epigenomics.com/>; rel=shortlink
varyUser-Agent,Accept-Encoding
cache-controlmax-age=0
expiresSun, 22 Sep 2024 08:41:36 GMT
content-encodinggzip
content-length6260
content-typetext/html; charset=UTF-8
dateSun, 22 Sep 2024 08:41:36 GMT
serverApache
statuscode200
http_versionHTTP/2

External factors

Blacklists
(Nice to have)
This website is not classified "for adult only".
This page is referenced by wikipedia.
This website has excellent links from other websites.
This page has backlinks from 261 referring domains.
This page has 2,208 backlinks.
This page has backlinks from 213 different ip addresses.
Facebook popularity
(Somewhat important)
The page has 0 shares and comments on Facebook.

Links from Wikipedia

You can find more links using Wikipedia search

Robots.txt

User-agent: *
Disallow: /wp-admin/
Allow: /wp-admin/admin-ajax.php

Similar sites

Search preview

www.epigenomics.com
Home - epigenomics

Most important keywords

Following keywords were found. You can check the keyword optimization of this page for each keyword.

KeywordResultRecheck
Epigenomics63%Check
Epigenomics AG52%Check
Epigenomics AG publishes financial45%Check
Financial43%Check
Preliminary43%Check
results43%Check
according43%Check
WpHG43%Check
German43%Check
Securities43%Check
Show more keywords and terms

Test up to 1.000 webpages of epigenomics.com with our free plan!

Try For Free
No trial. It's just free!

Cookie Policy

We use cookies to make our site work and also for analytics and advertising purposes. You can enable or disable optional cookies as desired. See the following links for more information.

Contact | Privacy

We need these so the site can function properly

So we can better understand how visitors use our website

So we can serve you tailored ads and promotions